Rani Therapeutics Inc. (RANI)
1.46
-0.07 (-4.58%)
At close: Mar 03, 2025, 3:59 PM
1.47
0.68%
After-hours: Mar 03, 2025, 04:00 PM EST
No 1D chart data available
| Bid | 1.47 |
| Market Cap | 83.64M |
| Revenue (ttm) | 5.46M |
| Net Income (ttm) | -55.96M |
| EPS (ttm) | -1.05 |
| PE Ratio (ttm) | -1.39 |
| Forward PE | -1.84 |
| Analyst | Buy |
| Ask | 1.56 |
| Volume | 374,365 |
| Avg. Volume (20D) | 1,031,037 |
| Open | 1.54 |
| Previous Close | 1.53 |
| Day's Range | 1.42 - 1.53 |
| 52-Week Range | 1.24 - 8.75 |
| Beta | 0.17 |
About RANI
Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics. The company develops the RaniPill capsule, a platform that is intended to replace subcutaneous or IV injection of biologics with oral dosing. Its product pipeline includes RT-101, an octreotide, which has completed Phase I clinical trial for the treatment of neuroendocrine tumors and acromegaly; RT-105, an anti-TNF-al...
Industry Biotechnology
Sector Healthcare
IPO Date Jul 30, 2021
Employees 140
Stock Exchange NASDAQ
Ticker Symbol RANI
Website https://www.ranitherapeutics.com
Analyst Forecast
According to 5 analyst ratings, the average rating for RANI stock is "Buy." The 12-month stock price forecast is $10, which is an increase of 584.93% from the latest price.
Buy 100.00%
Hold 0.00%
Sell 0.00%
3 weeks ago
+14.58%
Rani Therapeutics Holdings shares are trading high...
Unlock content with
Pro Subscription
3 weeks ago
+5.11%
Rani Therapeutics Holdings shares are trading higher after the company announced new pharmacokinetic and pharmacodynamic data from a preclinical study evaluating the oral delivery of the glucagon-like peptide-1 receptor agonist semaglutide administered via the RaniPill capsule.
